Throughout the last three months, 4 analysts have evaluated Arcus Biosciences (NYSE:RCUS), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.5, a high estimate of $42.00, and a low estimate of $30.00. This current average represents a 20.69% decrease from the previous average price target of $43.50.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Arcus Biosciences among financial experts becomes...
Login or create a forever free account to read this news
Sign up/Log in